Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other Malignancies

Abstract

OBJECTIVE:

To review the pharmacology, pharmacokinetics, and pivotal clinical trials for bevacizumab, emphasizing its use in colorectal cancer.

DATA SOURCES:

A PubMed/MEDLINE search was conducted (1966—April 2004) using the following terms: bevacizumab, Avastin, anti-VEGF, anti-angiogenesis, and colorectal cancer. Additional data sources included meeting abstracts, bibliographies from identified articles, and information from the manufacturer.

STUDY SELECTION AND DATA EXTRACTION:

Preclinical and clinical trials that used bevacizumab for the treatment of colorectal cancer and other malignancies were selected from the data sources. All published, randomized clinical trials evaluating bevacizumab in colorectal cancer were included in this review.

DATA SYNTHESIS:

Despite advances in chemotherapy, current therapeutic options for metastatic disease provide only temporary benefit for most patients. Bevacizumab is the first anti-cancer agent shown to provide benefit for patients with cancer by inhibiting angiogenesis. Bevacizumab has shown significant activity in the treatment of many cancers, including metastatic colorectal cancer. When used in combination with fluorouracil-based chemotherapy, bevacizumab improves overall response rates, time to progression, and survival in patients with metastatic colorectal cancer. Common toxicities associated with bevacizumab include hypertension, bleeding episodes, and thrombotic events.

CONCLUSIONS:

Although clinical knowledge on the effectiveness of bevacizumab is limited, early data indicate that it is a promising agent, with a novel mechanism of action, for patients with metastatic cancer, including colorectal cancer.

Keywords

anti-angiogenesis bevacizumab colorectal cancer

Get full access to this article

View all access options for this article.

References

Rosen

LS.

Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9(suppl 2):36–44.

Gordon

Margolin

Talpaz

Sledge

Jr Holmgren

Benjamin

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843–50.

Fernando

Hurwitz

HI.

Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003;30(suppl 6):39–50.

Jain

RK.

Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Semin Oncol 2003;29(suppl 16):3–9.

Neufeld

Cohen

Gengrinovitch

Poltorak

Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9–22.

Adams

Carder

Downey

Forbes

MacLennan

Allgar

Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000;60:2898–905.

Ferrara

Davis-Smyth

The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25.

Kim

Inhibition of vascular endothelial growth factor—induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841–4.

Warren

Yuan

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789–97.

10.

Borgstrom

Gold

DP.

Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19:4203–14.

11.

Lin

Nguyen

Mendoza

Escandon

Fei

Meng

Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288:371–8.

12.

Scheinberg

Sgouros

Junghans

RP.

Antibody-based immunotherapies for cancer. In: Chabner

Longo

, eds. Cancer chemotherapy and biotherapy. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 2001:850–90.

13.

Hsei

Novotny

Margolin

Gordon

Small

Griffing

Population pharmacokinetic (PK) analysis of bevacizumab (BV) in cancer subjects (abstract). Proc Am Soc Clin Oncol 2001;20:69a.

14.

Gaudreault

Lieberman

Kabbinavar

Bergsland

Novotny

Griffing

Pharmacokinetics (PK) of bevacizumab (BV) in colorectal cancer (CRC) (abstract). Clin Pharmacol Ther 2001;69:P25.

15.

Margolin

Gordon

Holmgren

Gaudreault

Novotny

Fyfe

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 2001;19:851–6.

16.

O'Connell

MJ.

A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989;63(suppl 6):1026–30.

17.

Petrelli

Douglass

Herrera

Russell

Stablein

Bruckner

The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7:1419–26.

18.

Saltz

Cox

Blanke

Rosen

Fehrenbacher

Moore

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–14.

19.

Douillard

Cunningham

Roth

Navarro

James

Karasek

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041–7.

20.

Goldberg

Sargent

Morton

Fuchs

Ramanathan

Williamson

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.

21.

Kabbinavar

Hurwitz

Fehrenbacher

Meropol

Novotny

Lieberman

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–5.

22.

Yang

Haworth

Sherry

Hwu

Schwartzentruber

Topalian

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–34.

23.

DeVore

Fehrenbacher

Herbst

Langer

Kelly

Gaudreault

A randomized Phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC (abstract). Proc Am Soc Clin Oncol 2000;19:485a.

24.

Giantonio

Levy

O'Dwyer

Meropol

Catalano

Benson

Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): Results from the Eastern Cooperative Oncology Group (ECOG) study E2200 (abstract). Proc Am Soc Clin Oncol 2003;22:255.

25.

Hurwitz

Fehrenbacher

Novotny

Cartwright

Hainsworth

Heim

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.

26.

Hurwitz

Fehrenbacher

Hainsworth

Heim

Berlin

Griffing

Bevacizumab in combination with 5-fluorouracil and leucovorin: A promising regimen for first-line metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol Gastrointestinal Cancers Symposium 2004. www.asco.org/ac/1,1003,_12-002643-00_18-0027-00_19-00497,00.asp (accessed 2004 May 26).

27.

Benson

Catalano

Meropol

O'Dwyer

Giantonio

BJ.

Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200 (abstract). Proc Am Soc Clin Oncol 2003;22:243.

28.

Product information. Avastin (bevacizumab). San Francisco: Genentech, February 2004.

29.

Kilickap

Abali

Celik

Bevacizumab, bleeding, thrombosis, and warfarin (letter). J Clin Oncol 2003;21:3542.

30.

Ostendorf

Kunter

Eitner

Loos

Regele

Kerjaschki

VEGF₁₆₅ mediates glomerular endothelial repair. J Clin Invest 1999;104:913–23.

31.

Chen

Gore-Langton

Cheson

BD.

Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology 2001;15:1017–26.

32.

Poon

Fan

Wong

Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207–25.